## **Technical Data Sheet**

# Purified Mouse Anti-Human c-erbB-2

#### **Product Information**

554300 **Material Number:**  $100 \mu g$ **Concentration:** 0.5 mg/ml 9G6 Clone:

Immunogen: Recombinant human c-erbB-2

Mouse IgG1 Isotype: QC Testing: Human Reactivity:

Storage Buffer: Aqueous buffered solution containing ≤0.09% sodium azide.

## Description

C-erbB-2 (also known as HER2/neu), a 185 kDa transmembrane glycoprotein, is a member of the type 1 growth factor receptor subfamily which also includes c-erbB-3, c-erbB-4 and the epidermal growth factor receptor (EGFR) (also known as c-erbB-1). Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. They have a common structure consisting of an extracellular domain, a transmembrane region, and a cytoplasmic sequence. The extracellular regions contain two cysteine-rich domains, and the intracellular regions have sequence homology to known tyrosine kinases. C-erbB-3 reactivity has been detected in proximal kidney tubules, mucosal epithelium in the gastointenstinal tract, and squamous epithelium in skin. Most other normal adult tissue show little or no reactivity with antibodies against c-erbB-2, including breast, ovary, spleen, liver, bone marrow, prostate, adrenal, and lung. However, c-erbB-2 is overexpressed in many human breast, stomach, ovary and bladder carcinomas. EGFR, c-erbB-3 and c-erbB-4 are also overexpressed in various human tumor cells, and it is thought that aberrant activation of type 1 growth factor kinase activities may contribute to tumor progression. Clone 9G6 recognizes human c-erbB-2. Recombinant human c-erbB-2 was used as immunogen.

## **Preparation and Storage**

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. Store undiluted at 4° C.

## **Application Notes**

Application

Immunohistochemistry-formalin (antigen retrieval required)	Routinely Tested
Immunohistochemistry-frozen	Routinely Tested
Flow cytometry	Reported
Immunoprecipitation	Reported

## **Recommended Assay Procedure:**

Positive control cells lines include MCF7 (ATCC HTB 22) and SK-BR-3 (ATCC HTB 30) human breast carcinoma cells.

## **Product Notices**

- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

#### References

Hesketh R. The Oncogene Handbook. New York: Academic Press; 1994:485-509.(Biology)

Carraway KL 3rd, Cantley LC, A neu acquaintance for erbB3 and erbB4; a role for receptor heterodimerization in growth signaling. Cell, 1994; 78(1):5-8.(Biology) Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res. 1991; 51(17):4575-4589.(Biology)

Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994; 173(1):65-75.(Clone-specific: Immunohistochemistry)

Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis. Am J Obstet Gynecol. 1993; 168(1):162-169.(Clone-specific: Immunohistochemistry)

Schwechheimer K, Laufle RM, Schmahl W, Knodlseder M, Fischer H, Hofler H. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol. 1994; 25(8):772-780.(Clone-specific: Immunohistochemistry)

## **BD Biosciences**

www.bdbiosciences.com

Europe Asia Pacific 888.259.0187 32.53.720.550 0120.8555.90 877.232.8995 65.6861.0633 55.11.5185.9995 For country-specific contact information, visit www.bdbiosciences.com/how\_to\_order/

Conditions: The information disclosed herein is not to be construed as a recommendation to use the above product in violation Conditions: In einformation disclosed neign is not to be construed as a recommendation to use the above product in violation of any patents. BD Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Becton Dickinson and Company is strictly prohibited.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. @2007 BD



Singleton TP, Niehans GA, Gu F, et al. Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry. *Hum Pathol.* 1992; 23(10):1141-1150.(Clone-specific: Immunohistochemistry)

Stàl O, Sullivan S, Sun XF, Wingren S, Nordenskjöld B. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry. Cytometry. 1994; 16(2):160-168.(Clone-specific: Flow cytometry, Immunohistochemistry)

van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. *N Engl J Med.* 1988; 319(19):1239-1245.(Clone-specific: Immunohistochemistry, Immunoprecipitation)

554300 Rev. 7 Page 2 of 2